Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

NCT07247786 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
Respiratory Tract Neoplasm

Interventions

BIOLOGICAL: Biological: Fecal Microbiota Transplantation
DRUG: Durvalumab
DRUG: Paclitaxel
DRUG: Carboplatin (AUC 6)

Sponsor

Fundación GECP